The BCL2L2 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population derived from HAP1 human chronic myeloid leukemia cells. This heterogeneous pool harbors targeted disruptions of the BCL2L2 gene, eliminating expression of the anti-apoptotic BCL-W protein. As a polyclonal product, it avoids clonal artifacts and provides a robust loss-of-function model for investigating apoptosis regulation, drug resistance, and genetic dependencies in a cancer-relevant setting.
HAP1 is a near-haploid cell line originating from the KBM-7 CML line, offering a stable karyotype advantageous for gene targeting. The parental cells carry the BCR-ABL1 fusion and rely on anti-apoptotic signals for survival. Single-allele disruption suffices to abolish protein function, simplifying knockout studies. This background is ideal for functional genomics and cell death pathway analysis, making BCL2L2 knockout a sensitized system to probe mitochondrial apoptosis in leukemia.
BCL2L2 encodes BCL-W, a pro-survival BCL-2 family member that inhibits mitochondrial outer membrane permeabilization by binding pro-apoptotic effectors BAX and BAK, and BH3-only proteins BIM, BID, PUMA, and NOXA. BCL-W is regulated upstream by STAT3, NF-??B, and MYC, and activated via JAK/STAT cytokine signaling. By sequestering BIM and BID, BCL-W blocks BAX/BAK-mediated cytochrome c release, apoptosome formation, and caspase-9/3 activation. Its disruption removes this inhibition, sensitizing cells to intrinsic apoptosis and highlighting BCL-W as a critical survival node.
In HAP1 CML cells, BCL2L2 knockout reduces the apoptotic threshold, enhancing sensitivity to chemotherapeutics and BH3 mimetics like venetoclax. This model is pertinent for studying resistance mechanisms in hematologic malignancies, where anti-apoptotic BCL-2 proteins are often deregulated. The polyclonal population mirrors tumor heterogeneity, enabling more realistic drug response profiling and synthetic lethality screens to uncover BCL-W-dependent vulnerabilities.
Applications include apoptosis assays with etoposide or ABT-199, measuring viability, caspase-3/7 activation, and cytochrome c release. Western blotting confirms BCL-W loss and monitors downstream markers. Co-immunoprecipitation delineates altered BCL-2 family interactions, and annexin V flow cytometry quantifies cell death. The model supports CRISPR screens for synthetic lethal interactions and validation of upstream regulators like STAT3. For further information, contact Ascent Research.
